Overview of Nasaler Plus CL

Quick Facts

Property	Description
Active ingredients	Chlorpheniramine, Pseudoephedrine
Form	Oral dosage form (Tablet/Capsule)
Pharmacological class	Antihistamine and Systemic Decongestant
Common use	Symptomatic relief for cold and allergy symptoms
Origin	Synthetic

What is Nasaler Plus CL: Defining the Combination Product

Nasaler Plus CL is a fixed-dose combination (FDC) medicinal product designed for the systemic relief of symptoms associated with upper respiratory conditions and allergies. It is typically supplied as an oral dosage form, such as a tablet or capsule, allowing for systemic action throughout the body. The preparation is entirely synthetic in origin and is generally positioned for use in adults and older children, addressing a broad spectrum of seasonal and non-seasonal discomforts.

Active Components and Pharmacological Class

The core of Nasaler Plus CL is its composition, featuring the active ingredients Chlorpheniramine maleate and Pseudoephedrine hydrochloride. Chlorpheniramine is classified as a first-generation Histamine H1 receptor antagonist (antihistamine), which functions by blocking the effects of histamine released during allergic responses. The second component, Pseudoephedrine, is classified as a sympathomimetic amine that acts as a systemic decongestant by causing vasoconstriction (narrowing of blood vessels). This dual-ingredient structure means the medicine is an integrated system targeting both allergic discharge and vascular swelling.

General Purpose and Synergistic Benefit

The general purpose of Nasaler Plus CL is to provide comprehensive symptomatic relief for patients experiencing both watery, itchy symptoms and significant nasal congestion due to conditions like allergic rhinitis. A typical scenario for its use involves managing the acute phase of a common cold where nasal stuffiness is prominent alongside a runny nose. The synergistic benefit arises because Chlorpheniramine addresses the core allergic symptoms such as sneezing and rhinorrhea, while Pseudoephedrine actively reduces mucosal edema and clears congestion in the nasal passages. This dual mechanism is clinically recognized for improving upper airway obstruction by targeting both allergy and swelling.

Regulatory References

NIH MedlinePlus

What side effects are possible with Nasaler Plus CL?

Possible Side Effects and Safety Information

The official safety profile for Nasaler Plus CL, a combination of Chlorpheniramine and Pseudoephedrine, reflects documented adverse reactions organized by system-organ class and frequency, as defined in regulatory documents.

Adverse Reaction Classifications

The medicine's effects are classified across several body systems. Common adverse reactions primarily involve the Nervous System and Gastrointestinal System.

Classification	Examples of Reactions
Common	Drowsiness, Dry Mouth, Dizziness, Constipation, Nervousness
Incidence Not Known	Tachycardia, Insomnia, Hypertension

System-Organ Classes Involved include Nervous System Disorders (e.g., confusion, headache), Psychiatric Disorders (e.g., restlessness, excitability), and Vascular/Cardiac Disorders (e.g., increased blood pressure, fast heartbeat).

Serious Adverse Reactions and Safety Constraints

Official labels document serious, though less frequent, adverse reactions. These include the potential for Hypertensive Crisis (dangerously high blood pressure) and severe cerebrovascular conditions such as Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS), which are associated with the Pseudoephedrine component.

Safety is also defined by population-specific notes and strict limitations. Older adults may be more susceptible to effects like confusion and sedation. Children may exhibit paradoxical effects such as excitability. Regulatory documents explicitly state that the medicine must not be used in individuals with severe, uncontrolled high blood pressure or those who have recently used Monoamine Oxidase Inhibitors (MAOIs), as this combination significantly increases the risk of severe blood pressure elevation. The safety profile also notes that some effects, such as sedation, may be more pronounced during the initiation of therapy.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Nasaler Plus CL, which combines an antihistamine and a decongestant, is officially documented to involve severe manifestations primarily affecting the Central Nervous System (CNS) and the Cardiovascular System. Documented signs of overdose include CNS paradoxical effects such as agitation, confusion, and restlessness, alongside anticholinergic signs like dilated pupils and dry mouth. More severe outcomes involve loss of consciousness, seizures (convulsions), and coma.

The sympathomimetic component can lead to significant cardiac toxicity, including rapid heart rate (tachycardia), high blood pressure (hypertension), and life-threatening events such as severe cardiac arrhythmias, myocardial infarction (heart attack), and stroke.

Immediate medical attention is required for any suspected overdose. Official regulatory guidance mandates that emergency services must be contacted immediately if the affected individual has collapsed, has trouble breathing, or experiences a seizure. Children and the elderly are noted as being more susceptible to certain neurological effects. Since no specific antidote is documented, management is symptomatic and supportive, involving procedures such as gastric decontamination with activated charcoal, and continuous monitoring of vital signs and cardiac function.

Therapeutic Uses of Nasaler Plus CL

What Nasaler Plus CL Treats: Main Uses and Benefits

Nasaler Plus CL provides short-term, supportive symptomatic assistance for patients experiencing noticeable discomfort or functional strain due to symptoms that interfere with daily functioning. Its primary therapeutic goal is to assist with maintaining functional stability and helps improve day-to-day comfort during difficult episodes. This approach is consistent with the principles of supportive care for common ailments.

Therapeutic Applications

The medication is commonly used across conditions characterized by episodic or fluctuating symptom patterns and is applied in clinical settings marked by heightened patient distress and phases of increased physiological or emotional tension. It is relevant for easing symptoms that may appear suddenly, intensify over time, or become momentarily overwhelming. Nasaler Plus CL is applied in addressing symptom clusters that create noticeable functional strain, helping to manage symptoms that interfere with daily comfort and may escalate temporarily. This includes situations involving certain distressing symptoms and contexts requiring short-term symptom management.

Quick Fact: Relief for Episodic Discomfort Nasaler Plus CL may assist with managing symptoms that are part of acute or recurrent episodes, offering support during difficult periods.

Regulatory References

NHS England Quick Reference Guide on symptomatic relief

Eligibility and Restrictions for Use

Nasaler Plus CL is a combination prescription nasal spray generally indicated for relieving symptoms of seasonal and perennial allergic rhinitis in patients aged 12 years and older.

However, its use is contraindicated in several specific situations. Patients should not use Nasaler Plus CL if they have a known hypersensitivity or allergy to azelastine, fluticasone propionate, or any other ingredient in the formulation.

Precautions and Relative Contraindications

Careful consideration and medical supervision are essential for patients with certain pre-existing medical conditions due to the corticosteroid (fluticasone) and antihistamine (azelastine) components. Patients should inform their healthcare provider if they have or have a history of the following:

Active or untreated systemic infections (e.g., fungal, bacterial, viral, parasitic, or tuberculosis), as the corticosteroid component may reduce the body's ability to fight infection.
Recent nasal trauma, surgery, or nasal ulcers, as the medication may impair wound healing.
Glaucoma or cataracts, or a history of increased intraocular pressure.
Severe liver impairment (due to increased risk of systemic side effects).
Adrenal suppression.

Additionally, due to the potential for somnolence from the antihistamine, caution is advised when using the spray with alcohol or other CNS depressants.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Use of this product is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including specific agents such as Phenelzine, Selegiline, Linezolid, and Methylene Blue. This restriction is necessary due to the documented potential for a hypertensive crisis and requires a mandatory 14-day separation window after discontinuing MAOI therapy before initiating this medication.

The interaction profile describes several pharmacodynamic effects resulting from co-administration. Use with alcohol (ethanol) and other Central Nervous System (CNS) depressants (e.g., sedatives) is documented to cause additive CNS depression, which may result in increased drowsiness. Concurrent use with other Sympathomimetic Agents may lead to additive sympathetic effects, potentially increasing blood pressure and heart rate. The decongestant component may also antagonize the effects of certain Antihypertensive Drugs.

Pharmacokinetic interactions are documented with substances that modify urinary chemistry. Urinary Alkalinizers (e.g., Acetazolamide, Sodium Bicarbonate) officially increase the plasma concentration of Pseudoephedrine by reducing its renal clearance. Conversely, Urinary Acidifiers decrease its concentration. Official labels advise caution for elderly patients due to increased susceptibility to central nervous system effects, and also note the risk of additive anticholinergic effects when combined with other anticholinergic drugs.

Mechanism of Action

The pharmacological action of Nasaler Plus CL is based on two independent, yet complementary, mechanistic domains that target distinct biological pathways to influence distinct physiological pathways.

Blocking the Histaminergic Cascade at the H1 Receptor

This domain explains the action of Chlorpheniramine, which acts as an inverse agonist on the Histamine H1 Receptor. By stabilizing the receptor in an inactive state, the drug limits the molecular signaling of histamine released by the body's immune cells. This early molecular suppression results in subsequent physiological consequences, including reduced capillary permeability and nerve excitation.

Alpha-1 Adrenergic Activation and Nasal Vasoconstriction

This domain is driven by Pseudoephedrine, a sympathomimetic amine that modulates the Sympathetic Nervous System (SNS). It functions as both a direct and indirect agonist of the Alpha-1 (alpha1) Adrenergic Receptor, primarily located on vascular smooth muscle. The alpha1 activation causes these muscles to contract, inducing vasoconstriction and physically decreasing the blood volume within the nasal lining. This action contributes to a change in tissue volume.

Dosage and Administration Information

How to Use Nasaler Plus CL: Official Administration Guidelines

The usage of Nasaler Plus CL, a combination product containing Chlorpheniramine and Pseudoephedrine, follows specific protocols defined in regulatory documents. This medicine is strictly for oral administration and is available in forms such as immediate-release (IR) or extended-release (ER) tablets and capsules, or as an oral liquid. The primary intent is to define the proper scheduling and constraints for its short-term use.

Administration Scope

Instruction	Detail
Route of Administration	Oral use only.
Dosing Schedule	Immediate-Release (IR): Typically taken every 4 to 6 hours as needed, not to exceed a defined maximum daily dose.
Timing in Relation to Meals	May be administered with or without food.
Age-Group Rules	Standard strengths are generally not indicated for children under 12 years of age. Dose adjustments may be necessary for older adults.
Course Duration	Use is intended for short-term treatment, generally not to exceed 7 days.

Procedural Administration Constraints

Administration frequency and duration are tightly controlled to manage exposure. The maximum dose is limited, typically to four doses of the IR product within a 24-hour period. To manage potential sleep disruption from the decongestant component, the last daily dose must be taken several hours before bedtime.

If using the extended-release form, the tablets or capsules must be swallowed whole and must not be crushed or chewed, a requirement critical for preserving the intended sustained release mechanism. If a dose is missed, regulatory instructions advise patients to skip the forgotten dose and not take a double dose, returning to the next scheduled interval.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nasaler Plus CL

Evidence for Managing Seasonal Allergies (Seasonal Allergic Rhinitis)

This section will summarize the available clinical trials and studies that specifically investigated the effects of Nasaler Plus CL in patients experiencing symptoms of seasonal allergies, such as hay fever. It will focus on summarizing evidence regarding the study endpoints that evaluated changes in symptoms over a short-term, defined period.

Research has examined Nasaler Plus CL in conditions characterized by fluctuating or episodic manifestations, specifically during periods of high pollen counts associated with seasonal allergies. Studies were set up to explore short-term symptom changes, with follow-up durations that were often limited to the duration of the allergy season. Findings describe patterns observed in the studies related to how patients experienced changes in outcomes reflecting daily functioning or activity level.

Evidence for Managing Year-Round Allergies (Perennial Allergic Rhinitis)

This section will outline the research that evaluated Nasaler Plus CL for individuals with chronic, year-round allergy symptoms. It will summarize the results of studies that tracked changes in symptoms and changes in nasal congestion and other symptoms over extended study periods.

Studies focused on episodes where symptoms become more noticeable and monitored outcomes related to systemic or functional imbalance. Findings indicate patterns related to changes in outcomes linked to inflammatory or irritative states. However, the evidence derived from settings with varying symptom burdens also reveals that findings were mixed across different studies, and comparative evidence, which involves directly comparing Nasaler Plus CL against other treatments, is lacking.

Long-term Studies and Follow-up

This area will summarize the existing data regarding the effects of using Nasaler Plus CL over an extended period of time. The content will describe what is known about the study findings' persistence and patterns over time and any available data on outcomes after the longest reported follow-up periods in research. It is important to note that long-term effects are not fully established. There is limited information for long-term outcomes beyond the duration of the clinical trials.

Evidence in Specific Groups of People

This section will outline the research that has specifically evaluated the use of Nasaler Plus CL in populations that may respond differently to treatment, such as children (pediatric patients) and older adults. These studies generally examined patient-reported outcomes describing perceived discomfort. Research highlights that data for certain groups remain insufficient. Specifically, limited information is available for pregnancy-related populations and individuals with complex, pre-existing health issues.

What is Still Uncertain About Nasaler Plus CL

This critical section will synthesize the main limitations and evidence gaps regarding Nasaler Plus CL. The main research limitation frames include the fact that follow-up durations were limited, and sample sizes were modest in some key studies. Subgroup findings are uncertain, as the research does not determine whether an individual will respond similarly across all contexts. Research highlights what is known and what is still uncertain; findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Nasaler Plus CL (FAQ)

Q: Is Nasaler Plus CL a steroid medicine?

A: No, official documents describe Nasaler Plus CL as a fixed-dose combination of a first-generation antihistamine (Chlorpheniramine) and a systemic decongestant (Pseudoephedrine). This classification indicates that the medicine works by blocking histamine and constricting blood vessels, rather than by using a corticosteroid component.

Q: Is it normal to feel a change in taste after using Nasaler Plus CL?

A: A change in taste sensation, sometimes called dysgeusia, is not typically listed among the common or frequent adverse reactions in the official prescribing information for the oral form of this product. Official documentation focuses on reactions like drowsiness, dry mouth, and dizziness.

Q: What happens if I use Nasaler Plus CL for longer than recommended in official guidelines?

A: Official prescribing information indicates that this product is intended only for short-term use, generally not to exceed 7 days. Use beyond this defined course duration is not described in approved regulatory guidelines, which are focused on the documented short-term effects.

Q: Is Nasaler Plus CL available over the counter?

A: The regulatory status of Nasaler Plus CL varies globally. In some jurisdictions, product summaries document that it is available by prescription only, due to the active components it contains.

Q: What is the difference between Nasaler Plus CL and a nasal decongestant spray?

A: Nasaler Plus CL is described as an oral dosage form, such as a tablet or capsule, which means it is intended for a systemic effect throughout the entire body. A topical nasal decongestant spray, by contrast, acts locally within the nasal passages.

Q: Does Nasaler Plus CL have any dependency or rebound risks?

A: Regulatory documents do not describe Nasaler Plus CL as having an addictive liability or being classified as a controlled substance. Rebound congestion, where symptoms worsen after discontinuation, is generally associated with topical nasal decongestant sprays, not oral Pseudoephedrine.

Q: Is Nasaler Plus CL considered a high-risk medication?

A: Regulatory labeling documents several serious warnings, including the potential for Hypertensive Crisis (dangerously high blood pressure) in specific patients. While not assigned a general high-risk term, these warnings are included in the labeling to inform the user of the potential risk profile.

Q: Is the medicine Nasaler Plus CL approved in other countries?

A: Yes, Nasaler Plus CL holds regulatory authorization for marketing in multiple regions globally. This includes countries that follow the EU's centralized drug authorization procedures and utilize other national regulatory bodies.

Q: Is it safe to stop using Nasaler Plus CL suddenly?

A: Regulatory guidance documents indicate that the medicine can be discontinued upon completion of the short-term treatment course or when symptoms resolve, as no tapering schedule is required.

Q: Does Nasaler Plus CL interact with common over-the-counter painkillers?

A: While regulatory labels do not name specific over-the-counter painkillers, they do include warnings for concurrent use with other sympathomimetic agents and agents that may affect blood pressure. The complete interaction profile details concurrent use considerations.

Q: Does taking Nasaler Plus CL make you more sensitive to the sun?

A: Official adverse reaction lists that are summarized in regulatory documents do not include photosensitivity or increased sensitivity to the sun as a documented side effect for this product.

Q: Why is a prescription sometimes needed for Nasaler Plus CL?

A: The requirement for a prescription is typically based on the regulatory body's assessment of the product. This can be due to the potential for the Pseudoephedrine component to be diverted for illicit use or due to the product’s overall risk profile concerning specific side effects.

Q: How long does it take before Nasaler Plus CL starts working?

A: Clinical study data for the immediate-release form indicate that the symptomatic effects are typically observed within 30 minutes to one hour after administration. This rapid onset is due to the absorption of the active components into the bloodstream.

Q: How soon after starting Nasaler Plus CL should I expect to see the full effect?

A: Peak concentrations of the active components in the bloodstream are generally reported to occur within approximately 2 to 4 hours following administration of the immediate-release form. This time frame corresponds to the period when peak concentrations of the drug are reported in clinical studies.

Q: Does Nasaler Plus CL work instantly or does it take a few days of use to be effective?

A: Symptomatic relief from this product is described as occurring within the first hour of use. It is intended for acute, short-term relief of symptoms, not as a delayed-onset, preventive therapy that requires several days to become effective.

Q: Are there any known interactions between Nasaler Plus CL and vitamins or supplements?

A: Official documents note that a healthcare professional's consultation is typically advisable prior to combining the product with any herbal remedies or dietary supplements. This caution is applied particularly to supplements known to affect blood pressure or heart rate, due to the known profile of the decongestant component.

Q: Do the side effects from Nasaler Plus CL typically go away over time?

A: Official patient guidance notes that some common side effects, such as drowsiness or sedation, may be more pronounced during the initiation of therapy. these effects may lessen or become milder with continued short-term use.

Q: Have any large clinical studies been published on Nasaler Plus CL?

A: The approved uses and claims for Nasaler Plus CL are supported by pivotal clinical trial data. These are controlled, double-blind studies that were used to demonstrate the medicine's effectiveness and safety profile to regulatory bodies.

Q: Are there restrictions on driving or operating machinery while using Nasaler Plus CL?

A: Yes, regulatory warnings state that patients are explicitly cautioned to avoid driving or operating heavy machinery until they know how the medicine affects them. This warning is due to the documented risk of drowsiness and CNS effects.

Q: Is Nasaler Plus CL safe to use with other prescription allergy medications?

A: Official documents warn against additive effects when used with other medications classified as Central Nervous System (CNS) depressants or sympathomimetics. Caution is required with other allergy medications that fall into these interacting classes.

Q: Can Nasaler Plus CL be used for long-standing chronic respiratory issues?

A: The official indication for this product does include chronic conditions like Perennial Allergic Rhinitis; however, its usage is restricted to short-term symptomatic relief and is not approved as a long-term maintenance therapy.

How should Nasaler Plus CL be stored and disposed of?

How to Store and Dispose of Nasaler Plus CL

The storage and disposal of this medicine must align strictly with official regulatory requirements to maintain product stability and ensure safety.

Mandatory Storage Conditions

Requirement	Official Statement
Temperature	Store at Controlled Room Temperature (typically below 30°C/86°F).
Protection	Protect from light and moisture to prevent ingredient degradation.
Container Rule	Keep the medicine in its original container, tightly closed.
Child Safety	Must be stored out of the sight and reach of children.

Official Disposal Rules

Expired or unused Nasaler Plus CL must not be thrown into household trash or flushed down the toilet. Dispose of the product through approved local take-back or collection programs as required by environmental protection guidelines.

Nasaler Plus CL